Terms: = Pancreatic cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL
2401 results:
1. Characterisation of the cell and molecular biological effect of peptide-based daunorubicin conjugates developed for targeting pancreatic adenocarcinoma (PANC-1) cell line.
Szász Z; Enyedi KN; Takács A; Fekete N; Mező G; Kőhidai L; Lajkó E
Biomed Pharmacother; 2024 Apr; 173():116293. PubMed ID: 38430628
[TBL] [Abstract] [Full Text] [Related]
2. A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma.
Enzler T; Nguyen A; Misleh J; Cline VJ; Johns M; Shumway N; Paulson S; Siegel R; Larson T; Messersmith W; Richards D; Chaves J; Pierce E; Zalupski M; Sahai V; Orr D; Ruste SA; Haun A; Kawabe T
Eur J Cancer; 2024 Apr; 201():113950. PubMed ID: 38422585
[TBL] [Abstract] [Full Text] [Related]
3. Irreversible Electroporation-Induced Inflammation Facilitates Neutrophil-Mediated Drug Delivery to Enhance pancreatic cancer Therapy.
Huang T; Wen X; Liang Y; Liu X; Zhao J; Long X
Mol Pharm; 2024 Apr; 21(4):1998-2011. PubMed ID: 38412284
[TBL] [Abstract] [Full Text] [Related]
4. Clinical impacts of positive intraepithelial neoplasia at pancreatic transection margin in pancreatic cancer surgery.
Takada S; Makino I; Katano K; Sugita H; Tokoro T; Gabata R; Okazaki M; Nakanuma S; Ikeda H; Toyama T; Yagi S
Pancreatology; 2024 May; 24(3):493-496. PubMed ID: 38378436
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial.
Qiu X; Lu C; Sha H; Zhu Y; Kong W; Tong F; Wang Q; Meng F; Liu B; Du J
Front Immunol; 2024; 15():1210859. PubMed ID: 38361920
[TBL] [Abstract] [Full Text] [Related]
6. Pancreas-related persisting sequelae in ALL survivors with a history of asparaginase-associated pancreatitis: A part of the ALL-STAR study.
Skipper MT; Birkebæk N; Jensen RB; Rank CU; Tuckuviene R; Wehner PS; Lambine TL; Hørlyck A; Schmiegelow K; Frandsen TL; Andrés-Jensen L; Albertsen BK
Eur J Haematol; 2024 Jun; 112(6):944-956. PubMed ID: 38351310
[TBL] [Abstract] [Full Text] [Related]
7. Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.
Yang X; Lian B; Zhang N; Long J; Li Y; Xue J; Chen X; Wang Y; Wang Y; Xun Z; Piao M; Zhu C; Wang S; Sun H; Song Z; Lu L; Dong X; Wang A; Liu W; Pan J; Hou X; Guan M; Huo L; Shi J; Zhang H; Zhou J; Lu Z; Mao Y; Sang X; Wu L; Yang X; Wang K; Zhao H
BMC Med; 2024 Jan; 22(1):42. PubMed ID: 38281914
[TBL] [Abstract] [Full Text] [Related]
8. Implementation and outcome of minimally invasive pancreatoduodenectomy in Europe: a registry-based retrospective study - a critical appraisal of the first 3 years of the E-MIPS registry.
Emmen AMLH; de Graaf N; Khatkov IE; Busch OR; Dokmak S; Boggi U; Groot Koerkamp B; Ferrari G; Molenaar IQ; Saint-Marc O; Ramera M; Lips DJ; Mieog JSD; Luyer MDP; Keck T; D'Hondt M; Souche FR; Edwin B; Hackert T; Liem MSL; Iben-Khayat A; van Santvoort HC; Mazzola M; de Wilde RF; Kauffmann EF; Aussilhou B; Festen S; Izrailov R; Tyutyunnik P; Besselink MG; Abu Hilal M;
Int J Surg; 2024 Apr; 110(4):2226-2233. PubMed ID: 38265434
[TBL] [Abstract] [Full Text] [Related]
9. Therapy-induced senescent cancer cells exhibit complement activation and increased complement regulatory protein expression.
Abu-Humaidan AH; Ismail MA; Ahmad FM; Al Shboul S; Barham R; Tadros JS; Alhesa A; El-Sadoni M; Alotaibi MR; Ababneh NA; Saleh T
Immunol Cell Biol; 2024 Apr; 102(4):240-255. PubMed ID: 38265162
[TBL] [Abstract] [Full Text] [Related]
10. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
[TBL] [Abstract] [Full Text] [Related]
11. Intracellularly delivered human lactoferrin functions as an activator of Na
Kurimoto D; Hue Anh TD; Kasama R; Sato A
Biochem Biophys Res Commun; 2024 Feb; 695():149480. PubMed ID: 38215552
[TBL] [Abstract] [Full Text] [Related]
12. The relationship between DNA mismatch repair gene and other prognostic parameters in pancreatic adenocarcinoma.
Urganci N; Kepil N; Ergun S; Bakkaloglu OK
J Surg Oncol; 2024 Apr; 129(5):876-884. PubMed ID: 38173349
[TBL] [Abstract] [Full Text] [Related]
13. Investigation of iso-propylchaetominine anticancer activity on apoptosis, cell cycle and Wnt signaling pathway in different cancer models.
Karamad V; Sogutlu F; Ozkaya FC; Shademan B; Ebrahim W; El-Neketi M; Avci CB
Fitoterapia; 2024 Mar; 173():105789. PubMed ID: 38158162
[TBL] [Abstract] [Full Text] [Related]
14. Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected pancreatic cancer.
Murthy P; Zenati MS; AlMasri SS; DeSilva A; Singhi AD; Paniccia A; Lee KK; Simmons RL; Bahary N; Lotze MT; Zureikat AH
J Natl Compr Canc Netw; 2023 Dec; 22(1D):e237070. PubMed ID: 38150819
[TBL] [Abstract] [Full Text] [Related]
15. Air quality and cancer risk in the All of Us Research Program.
Craver A; Luo J; Kibriya MG; Randorf N; Bahl K; Connellan E; Powell J; Zakin P; Jones RR; Argos M; Ho J; Kim K; Daviglus ML; Greenland P; Ahsan H; Aschebrook-Kilfoy B
Cancer Causes Control; 2024 May; 35(5):749-760. PubMed ID: 38145439
[TBL] [Abstract] [Full Text] [Related]
16. Structure-Activity Relationship of FL118 Platform Position 7 Versus Position 9-Derived Compounds and Their Mechanism of Action and Antitumor Activity.
Wang W; Ling X; Wang R; Xiong H; Hu L; Yang Z; Wang H; Zhang Y; Wu W; Singh PK; Wang J; Li F; Li Q
J Med Chem; 2023 Dec; 66(24):16888-16916. PubMed ID: 38100041
[TBL] [Abstract] [Full Text] [Related]
17. Associations between Two Dietary Quality Scores and pancreatic cancer Risk in a US National Prospective Cohort Study.
Hoyt M; Song Y; Gao S; O'Palka J; Zhang J
J Am Nutr Assoc; 2024; 43(4):345-355. PubMed ID: 38096044
[TBL] [Abstract] [Full Text] [Related]
18. The association between food access and frailty among older adults with gastrointestinal malignancies-The CARE Registry.
Fowler ME; Harmon C; Sharafeldin N; Baker E; Oates G; Nassel A; Clausing D; Giri S; Williams GR
Cancer; 2024 Apr; 130(7):1083-1091. PubMed ID: 38059840
[TBL] [Abstract] [Full Text] [Related]
19. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma.
Katz MHG; Petroni GR; Bauer T; Reilley MJ; Wolpin BM; Stucky CC; Bekaii-Saab TS; Elias R; Merchant N; Dias Costa A; Lenehan P; Cardot-Ruffino V; Rodig S; Pfaff K; Dougan SK; Nowak JA; Varadhachary GR; Slingluff CL; Rahma O
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040420
[TBL] [Abstract] [Full Text] [Related]
20. Targeted delivery of genistein for pancreatic cancer treatment using hyaluronic-coated cubosomes bioactivated with frankincense oil.
Sallam NG; Boraie NA; Sheta E; El-Habashy SE
Int J Pharm; 2024 Jan; 649():123637. PubMed ID: 38008234
[TBL] [Abstract] [Full Text] [Related]
[Next]
